ACHV - Achieve Life Sciences, Inc.
| Previous Close | 2.1600 |
| Open | 2.1200 |
| Bid | 2.1400 x 1400 |
| Ask | 2.1600 x 800 |
| Day's Range | 2.1100 - 2.2200 |
| 52 Week Range | 1.0400 - 5.2500 |
| Volume | 20,920 |
| Avg. Volume | 128,551 |
| Market Cap | 17.491M |
| Beta (3Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6060 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- PR Newswire
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo. Topline results, reported in June of 2019, have led to the selection of 3.0 mg, three times daily (TID) dosing for future Phase 3 development. The 3.0 mg TID treatment arm demonstrated a 54% abstinence rate at week 4, compared to 16% for placebo (p
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Achieve Life Sciences, Inc. (NASDAQ:ACHV)?
Anyone researching Achieve Life Sciences, Inc. (NASDAQ:ACHV) might want to consider the historical volatility of the...
- PR Newswire
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
The event will include an updated data presentation by the primary investigator of the Phase 2b ORCA-1 trial of cytisinicline. It will also feature a panel discussion moderated by leading healthcare analysts, Michael Higgins from Ladenburg Thalmann and Jason McCarthy from Maxim Group, with participation from four esteemed medical experts in the field of smoking cessation.
- PR Newswire
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia , Sept. 4, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- Zacks Small Cap Research
ACHV: SRNT Presentation Next on Agenda
Achieve Life Sciences, Inc. (ACHV) released its second quarter results for 2019 and filed the companion 10-Q on August 8, 2019. No revenues were reported for the development stage company and operational expenses totaled $3.7 million producing a net loss of ($0.50) per share. During the three month period, the company completed the ORCA-1 Phase IIb study, was granted a patent for a new formulation of cytisinicline and reported statistically significant improvement in quit rates for cytisinicline.
- PR Newswire
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
In the news release, Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update, issued 08-Aug-2019 by Achieve Life Sciences, Inc. over PR Newswire, ...
- PR Newswire
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
SEATTLE and VANCOUVER, British Columbia , July 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- PR Newswire
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, July 23, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced it has extended its strategic collaboration with the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH).
- Simply Wall St.
Did You Manage To Avoid Achieve Life Sciences's (NASDAQ:ACHV) Painful 55% Share Price Drop?
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
- Benzinga
Achieve Life Sciences Says Mid-Stage Data For Smoking Cessation Drug Accepted For Presentation At Conference
Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV ) traded sharply higher Friday morning before paring those gains. Achieve, which develops Cytisinicline – a plant-based ...
- PR Newswire
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE, Wash. and VANCOUVER, British Columbia, June 21, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14, 2019. The abstract "A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers" and oral presentation will include updated cytisinicline data from the recently completed ORCA-1 trial. Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.
- Zacks Small Cap Research
ACHV: ORCA-1 Topline Results and Comparison
Achieve Life Sciences, Inc. (ACHV) reported topline results from its Phase IIb Ongoing Research of Cytisinicline for Addiction (ORCA)-1 trial which was launched in October 2018. The study enrolled 254 subjects, employing six arms: four with active drug and two with placebo. The primary endpoint for the ORCA-1 study was the self-reported reduction in daily smoking.
- PR Newswire
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
SEATTLE and VANCOUVER, British Columbia, June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced positive results from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. The primary endpoint was the reduction in daily smoking, a self-reported measure. Three of the four cytisinicline treatment arms demonstrated a statistically significant improvement, as defined in the protocol as p
- PR Newswire
Achieve Receives $4.2 Million from Exercise of Warrants
SEATTLE and VANCOUVER, British Columbia, June 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it entered into an agreement with a single investor to exercise outstanding warrants that will provide an aggregate of $4.2 million in total proceeds. The proceeds from the warrant exercise would bring Achieve's pro-forma cash balance to approximately $13.9M as of March 31, 2019, based on its most recently reported financial results. Pursuant to the agreement, the investor agreed to exercise outstanding warrants to purchase 270,313 shares of the Company's common stock, with an exercise price of $3.1445 per share and outstanding warrants to purchase 837,500 shares of Common Stock with an exercise price of $4.00 per share.
- Zacks Small Cap Research
ACHV: 1Q:19 Financial & Operational Update
Achieve Life Sciences, Inc. (ACHV) released its first quarter results for 2019 and filed the companion 10-Q on May 15, 2019. Since our previous update two months ago, the company announced the end of the ORCA-1 trial which is expected to produce topline results mid-year.
- PR Newswire
Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
SEATTLE and VANCOUVER, British Columbia, May 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (No. 10,300,050) on succinate salt of cytisinicline and use thereof. Applications are pending in the European Patent Office, Japan, China, Australia, Canada, and South Korea. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.
CNW GroupAchieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
